There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vascular Biogenics (VBLT) and Marinus (MRNS) with bullish sentiments.
Vascular Biogenics (VBLT)
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Vascular Biogenics today and set a price target of $2.00. The company’s shares closed last Monday at $1.04.
According to TipRanks.com, DeGeeter is a 1-star analyst with an average return of -6.0% and a 32.5% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Molecular Templates, and Cidara Therapeutics.
Currently, the analyst consensus on Vascular Biogenics is a Moderate Buy with an average price target of $3.50, implying a 250.0% upside from current levels. In a report released today, JonesTrading also reiterated a Buy rating on the stock with a $3.75 price target.
See today’s analyst top recommended stocks >>
Marinus (MRNS)
Oppenheimer analyst Jay Olson maintained a Buy rating on Marinus today. The company’s shares closed last Monday at $1.62.
According to TipRanks.com, Olson has 0 stars on 0-5 star ranking scale with an average return of -14.8% and a 28.3% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, ACADIA Pharmaceuticals, and Enanta Pharmaceuticals.
Currently, the analyst consensus on Marinus is a Moderate Buy with an average price target of $6.00, a 361.5% upside from current levels. In a report issued on March 17, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MRNS:
